DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Antivirals Market Analysis: By Type (Hepatitis-C, HIV, Herpes, Hepatitis-B, Influenza Other Antivirals); By Action (DNA polymerase inhibitors, NS3 Protease inhibitors, Reverse transcriptase inhibitors and OthersWith Forecast (2016-2021)" report to their offering.
Antivirals are drugs that are used to treat viral infections. While a majority of antivirals are used for treating specific viral infections, there are a few broad-spectrum antivirals to treat other viral infections. As opposed to antibiotics that actually destroy the target pathogen, antivirals only inhibit the growth of the pathogen. Antivirals have the advantage of not causing any side effects and focus on inibiting the replication of the virus. An increase in the disease afflicted population across the globe is one of the major drivers for this market. Apart from this, increasing levels of awareness coupled with the launch of newer and more effective drugs, this market has tremendous opportunities in emerging economies.
The report provides an exhaustive overview of antiviral research and development pipeline. A huge amount of research and development is underway to extend the range of antivirals to treat other pathogens. Also, with the tendency of viruses to mutate and become drug resistant, the need of the hour is to develop and refresh the pipeline of antivirals with new therapies. A section on patent analysis is also included.
- Novartis AG
- Gilead Sciences Inc.
- Johnson and Johnson
- Abbott Laboratories
- AstraZeneca AB
- BoehringerIngelheim Corporation
1. Antivirals Market Overview
2. Executive Summary
3. Antivirals Market Landscape
4. Antivirals Market Forces
5. Antivirals Market - Strategic Analysis
6. Antivirals Market By Type
7. Antivirals Market By Actions
8. Antivirals Market By Geography
9. Antivirals Market Entropy
10. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/rctb46/antivirals_market